Advertisement

Topics

"EcoTT CO., LTD.∨derfield=date∨derval=DESC" News Stories

04:59 EDT 17th July 2019 | BioPortfolio

Here are the most relevant search results for "EcoTT CO., LTD.∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about EcoTT CO., LTD.∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EcoTT CO., LTD.∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list EcoTT CO., LTD.∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of EcoTT CO., LTD.∨derfield=date∨derval=DESC Companies for you to search.

Showing "EcoTT derfield date derval DESC" News Articles 1–25 of 4,800+

Tuesday 16th July 2019

Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency

Astellas adds a large-market drug candidate to its regenerative medicine portfolio, while Frequency Therapeutics almost doubles its fundraising to date...  


Senseonics Announces Public Offering of Common Stock

Senseonics Holdings, Inc. (“Senseonics”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $25.0 million of its shares of common stock. In addition, Senseonics anti...

Senseonics Announces Commencement of Convertible Notes Offering

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 ...


Senseonics Holdings, Inc. Reports Preliminary Second Quarter 2019 Net Revenue

Preliminary second quarter net revenue between $4.4M and $4.7M Nearly 4,500 Eversense® System prescriptions written in the U.S. as of June 30, 2019 Expanded commercial coverage to 76M lives as of June 30, 2019 Senseonics Holdings, Inc. (“Senseonics” or “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, im...

Valley Presbyterian Hospital Receives Get With The Guidelines-Stroke Bronze Quality Achievement Award

American Heart Association Award recognizes Valley Presbyterian Hospital’s commitment to quality stroke care Valley Presbyterian Hospital has received the American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Bronze Quality Achievement Award. The award recognizes the hospital’s commitment to ensuring stroke patients receive the most appropriate treatment...

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

Ipsen: Disclosure of Transactions in Own Shares Between 08/07/2019 And 12/07/2019

Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification code of thefinancial instrument Daily total volume(in number of sh...

Contagion® Adds MAD-ID® to Its Strategic Alliance Partnership Program

Contagion®, the nation’s leading multimedia resource dedicated to providing up-to-date, disease-specific information to health care practitioners and specialists in the field of infectious diseases, announces the addition of Making A Difference in Infectious Diseases (MAD-ID®) to its Strategic Alliance Partnership (SAP) program. “We are very excited to be partnering with the MAD-ID® org...

Sigrid Therapeutics announces that all patients have completed treatment with SiPore15 in the STAR Trial

First-in-Class MSP (mesoporous silica particle) based therapy targets blood sugar and other metabolic risk factors. Stockholm, Sweden, July 16, 2019 – Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies for metabolic diseases and disorders, today announces that all patients have completed treatment with SiPore15 in the STAR trial. Development is well on...

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula

CE Marked Bi-Flow is the only cannula designed to prevent leg ischemia during cardiac procedures requiring femoral artery cannulation LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the on...

‘Technological Feat’ Of Research On Old Tissue Serves Up Evidence HIV Started Infecting Humans In Early 1900s

Scientists at the University of Arizona examined a tissue sample that dates back to the 1960s, the oldest sample of HIV to date, and concluded the virus jumped from primates earlier than expected. The researchers tested 1,652 pathology samples and found the HIV sequence in one. Public health news also looks at: CRISPR baby editing guidelines, gun violence, paramedics' mental health, shootings in h...

Qiagen Biorobot 8000 HAW-00000079 Pump Control Board

$115.00 (0 Bids)End Date: Monday Jul-22-2019 20:04:11 PDTBid now | Add to watch list Biotech365 : Qiagen Biorobot 8000 HAW-00000079 Pump Control Board BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool or a Bioinformatic … Continue reading →

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Xultophy, insulin degludec / liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 18/09/2014, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Xultophy, insulin degludec / liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 18/09/2014, Revision: 11, Status: Authorised

TILT Holdings Announces U.S. $125 Million Convertible Note Financing

Proposed financing would provide the capital to accelerate the runway for growth across business units and continue the TILT mission to deliver value to shareholders TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQB: SVVTF) today announced that it has signed a binding term sheet for a private placement of US $125 million from a syndicate of institutional investors (the “F...

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement,Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement,Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Candidiasis, Date of authorisation: 25/04/2008, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Candidiasis, Date of authorisation: 25/04/2008, Revision: 13, Status: Authorised

Did You Invest In Galapagos?

Shares of Galapagos NV (GLPG), which touched an all-time high of $174.63 in intraday trading on Monday, have gained 90 percent year-to-date. GLPG was trading around $55 when we alerted our premium subscribers to this stock on July 17, 2015.

Veterinary medicines European public assessment report (EPAR): Nexgard Spectra, afoxolaner / milbemycin oxime, Date of authorisation: 14/01/2015, Revision: 4, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nexgard Spectra, afoxolaner / milbemycin oxime, Date of authorisation: 14/01/2015, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ammonaps, sodium phenylbutyrate, Ornithine Carbamoyltransferase Deficiency Disease,Citrullinemia,Carbamoyl-Phosphate Synthase I Deficiency Disease, Date of authorisation: 07/12/1999, Revision: 19,

Human medicines European public assessment report (EPAR): Ammonaps, sodium phenylbutyrate, Ornithine Carbamoyltransferase Deficiency Disease,Citrullinemia,Carbamoyl-Phosphate Synthase I Deficiency Disease, Date of authorisation: 07/12/1999, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Erectile Dysfunction, Date of authorisation: 21/11/2014, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Erectile Dysfunction, Date of authorisation: 21/11/2014, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Volibris, ambrisentan, Hypertension, Pulmonary, Date of authorisation: 20/04/2008, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Volibris, ambrisentan, Hypertension, Pulmonary, Date of authorisation: 20/04/2008, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Jorveza, budesonide, Esophageal Diseases, Date of authorisation: 08/01/2018, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Jorveza, budesonide, Esophageal Diseases, Date of authorisation: 08/01/2018, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lyxumia , lixisenatide, Diabetes Mellitus, Type 2, Date of authorisation: 31/01/2013, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Lyxumia , lixisenatide, Diabetes Mellitus, Type 2, Date of authorisation: 31/01/2013, Revision: 9, Status: Authorised


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks